Futura Medtech Expands Medtech Platform, Invests in Bengaluru-based Rivarp Medical

Rivarp Medical produces devices and implants for the orthopedics, neurosurgery, and interventional cardiology sectors. This investment introduces these therapeutic areas to Futura Medtech as Jashvik Capital works to develop a multi-category medical device business.

Jashvik Capital has announced that its portfolio company, Futura Medtech, has made a strategic investment in Rivarp Medical, a Bengaluru-based manufacturer specializing in medical devices and implants for orthopedics, neurosurgery, and interventional cardiology.

This transaction marks the third investment under the Futura Medtech platform and supports Jashvik Capital’s strategy of developing a scaled, multi-category medical devices business with strong domestic and global reach. Earlier, the platform invested in Dolphin Sutures in October 2024 and Suture Planet in July 2025.

Founded in 2016, Rivarp Medical has built a differentiated product portfolio across high-growth therapeutic segments, supported by in-house manufacturing capabilities and key international regulatory approvals, including EU MDR and US FDA certifications. The company distributes its products across India and global markets through a network of more than 100 channel partners.

“Medical devices and consumables are a large and fast-growing opportunity in India and international markets. Through these acquisitions, our management team intends to drive synergies related to innovation, manufacturing, and sales and distribution channels," said Naresh Patwari, founder of Jashvik Capital.

“Partnering with Futura Medtech provides us with access to capital to invest in innovation and to deepen customer engagement. Futura has deep distribution in various channels that are complementary to the distribution strengths of Rivarp,” MT Naidu, founder of Rivarp, said in the statement.

Stay tuned for more such updates on Digital Health News